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doi:10.1016/j.kjms.2010.12.010Abstract Kayexalate (sodium polystyrene sulfonate) is a cation-exchange resin used to treat
patients with hyperkalemia. Concomitant administration of kayexalate and sorbitol may
induce gastrointestinal injury, which is potentially lethal. However, this well-documented
complication is often underrecognized both clinically and pathologically. We propose a typical
case along with colonoscopic photos and microscopic pictures. Additionally, we also present
a review of the literature on this rare drug-induced side effect.
摘要 凱鉀力寧散 (Kayexalate; sodium polystyrene sulfonate)是一種臨床上常用的陽離子交換
樹脂，功用為降低病人的血鉀濃度。當使用山梨醣醇(sorbitol) 作為凱鉀力寧散的溶劑時，這種
藥物組合可能會造成致命的腸道壞死。但是，不管是在臨床上或病理上，醫師常常忽略這個已被
證實的藥物副作用。在我們提出的這個典型病例中，該病人在口服凱鉀力寧散與山梨醣醇之後，
併發了典型的壞死性大腸炎；我們也附上內視鏡與病理照片，來闡述其可觀察到的變化。最後，
我們也針對這個罕見但致命的藥物副作用，做詳細的文獻整理。
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.of Pathology, National Taiwan University Hospital Yun-Lin Branch, No. 579, Section 2,Yunlin Road,
an.
.com (M.-S. Hsieh).
vier Taiwan LLC. All rights reserved.
Figure 1. The colonscopy showed multiple ulcers over
splenic flexure. The endoscopic appearance of the colon ulcers
included scattered erosion, longitudinal ulcerations, and
sharply defined segment of involvement. The pictures were
compatible with ischemic colitis.
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Drug-related gastrointestinal tract injuries are well docu-
mented, but underrecognized condition [1]. Among such
injuries, concomitant use of kayexalate and sorbitol can
cause severe intestinal ischemic necrosis, which may lead to
fatal outcome [2e10]. Patients with predisposing factors,
such as uremia, postoperation, and transplantation, are
more vulnerable to such “kayexalate in sorbitol-associated
gastrointestinal tract injuries” [6,7,9,10]. For clinicians,
awareness of this rare but probably lethal complication is
crucial, because early detection may initiate applicable
management promptly. Medication history should be
searched carefully for young patients with unexplainable
gastroenteritis [1]. For pathologists, identifying the kayex-
alate crystal in necrotic gastrointestinal tissue is also
important, because early feedback to the clinician can lead
to the cease ofmedication and the avoidance ofmore serious
adverse outcomes.
Case presentation
A 30-year-old man presented at our emergency department
with bloody stool for 1 day.
The patient had a medical history of hypertension,
chronic renal failure under hemodialysis for 4 years, and
left ureteral urothelial carcinoma status posttransurethral
resection of bladder tumor and systemic chemotherapy
with gemcitabine. He received follow-up for the above
diseases at another hospital. Owing to massive bloody
stool for several times during last 24 hours, he visited our
emergency department. Although the patient presented
with a pale appearance and mild shortness of breath, the
initial vital signs were stable. Physical examination
revealed no notable findings except pale conjunctiva. The
patient reported no recent abdominal pain, diarrhea,
nausea, or fever.
Initial laboratory examination detected anemia with
hemoglobulin 5.9 g/dL, leukocytosis with white blood cell
count 27,700/mm3, and mild hyperkalemia (5.7 mM). The
patient was treated with kayexalate 30 g and 70% sorbitol
60 mL by oral route, followed by kayexalate 60 g enemas
and calcium gluconate/insulin/glucose cocktail because of
continuously rising potassium level. Empirical antibiotics
cefmetazole and component therapy were also adminis-
tered for suspected intraabdominal infection and anemia.
Despite of these treatments, intermittent episodes of
bloody stool continued to occur, and the patient was
admitted to our gastrointestinal ward for further manage-
ment. The patient underwent colonoscopy 3 days later
(Fig. 1). Colonoscopy revealed multiple ulcers, which were
subjected to biopsy, at the splenic flexure and transverse
colon. The ulcers were isolated and well demarcated. Some
linear ulcers were observed along the longitudinal axis of
the colon. An ulcer with exposed vessels, where bosmin
injection and heater probe coagulation were applied, was
noted at the splenic flexure. Based on distribution and
pattern of ulcers, ischemic colitis was identified as the
most likely etiology.
No more bloody stool occurred after colonoscopic
examination. The patient was discharged with stablestatus. On outpatient follow-up 1 week later, the patient
reported no hematochezia or other discomforts.
The submitted specimen from endoscopic biopsy showed
some necrotic debris adjacent to eroded colonic mucosa. A
few basophilic and rhomboid crystals with fish-scale-like
mosaic pattern were identified, either floating in ulcerated
debris (Fig. 2A) or embedded in colonic lamina propria
(Fig. 2B). These crystals were magenta in periodic acid-
Schiff stain (Fig. 3A), and unstained in Congo red stain
(Fig. 3B). The morphology and histochemical properties
were consistent with kayexalate crystals [12].
The nonnecrotic part of colonic tissue exhibited erosion
with granulation tissue formation. Focal stromal hyaliniza-
tion was observed, but the adjacent glands were not
withered. The overall picture was compatible with ischemic
colitis. Cytomegalovirus stain demonstrated no evidence of
cytomegalovirus infection. No infiltrating epithelial cells
were highlighted by cytokeratin stain. Features of inflam-
matory bowel disease, infectious disease, and malignancy
were absent in this case. Restated, except the kayexalate
crystals, no other identifiable causes existed to explain the
colonic necrosis.
Considering the clinical information and microscopic
findings, “colonic necrosis associated with kayexalate
(sodium polystyrene sulfonate) in sorbitol” was diagnosed.
Discussion
Kayexalate (sodium polystyrene sulfonate) is a cation-
exchange resin used to treat patients with hyperkalemia
and is administered either orally or via an enema. This drug
was popularized in 1961 and approved for use in the United
States in 1975. After entering the gastrointestinal tract,
sodium ions of kayexalate are exchanged for potassium
ions, which are later excreted into the stool [2]. Beside
potassium ions, kayexalate may also bind some calcium ions
Figure 2. Kayexalate crystals (A) either floating in ulcerated debris (B) or embedded in colonic lamina propria [hematoxylin and
eosin; original magnification (A) 400, (B) 200].
Kayexalate in sorbitol associated colonic necrosis 157in the intestinal lumen. This binding complex can lead to
stool impact and decrease the efficiency of potassium
clearance. To avoid such side effects, kayexalate was once
frequently administered with hypertonic sorbitol, a laxa-
tive acting via the mechanism of osmotic diarrhea [3].
In 1987, Lillemoe et al. [4] described the association
between colonic necrosis and concomitant use of kayex-
alate in sorbitol. Five uremic patients with hyperkalemia
were reported to develop colonic necrosis after enema
administration of kayexalate in sorbitol. Four of the five
patients later died from intestinal complications. After
that, oral route of kayexalate in sorbitol was noted to be
associated with similar ischemic necrosis, involving both
upper and lower gastrointestinal tract. In contrast to the
potentially lethal ileocolonic necrosis, upper gastrointes-
tinal tract injury induced by this drug combination was
followed by a more indolent clinical course. A possible
explanation was proposed, suggesting that ischemic insults
that affect ileocolonic regions are more prone to progress
into transmural infarction than those involving the upper
gastrointestinal tract [3,6].
In patients concomitant using kayexalate and sorbitol,
only 0.27e1.8% developed intestinal injuries in following
1e7 days [6,7]. Early reports indicated that critical patients
with uremia and recent history of surgery tended to be
more vulnerable. In these conditions, mechanisms such as
mesenteric vasoconstriction or delayed gastrointestinal
transit might cause gastrointestinal mucosa in relatively
hypoxic status, therefore increased susceptibility to drug-Figure 3. Staining properties of kayexalate crystals. (A) Magenta
Unstained in Congo red stain (original magnification 400).related ischemic effect [6,7,9,10]. However, a case series
in 2009 revealed that even in noncritical patients with rare
comorbidities, simultaneous administration of kayexalate
and sorbitol might result in intestinal necrosis, which was as
lethal as that seen in critical patients [8].
The precise mechanism via which kayexalate in sorbitol
induces gastrointestinal necrosis remains unclear. In the
experimental evidence proposed by Lillemoe, sorbitol was
thought to be responsible for ischemic enterocolitis,
probably via the mechanism of osmotic ischemia or pros-
taglandin effect [3,4,11]. Elimination of sorbitol from
kayexalate oral solution and enema was recommended
[2,5,8]. However, the applicability of the animal model to
human beings remains uncertain. Furthermore, cases of
intestinal necrosis have been reported in patients receiving
“sorbitol-free” kayexalate enema [14]. Consequently,
some authors suggested that methods other than kayex-
alate resin should be considered first when managing
patients with hyperkalemia [8,15]. Physicians prescribing
kayexalate should be aware of the potential for fatal side
effects [2,8].
The clinical symptoms caused by kayexalate in sorbitol-
related gastrointestinal necrosis are nonspecific and
frequently underrecognized. The endoscopic findings were
as usual ischemic enterocolitis. However, useful hints still
come from detailed medication history and unusual clinical
presentations. For example, young patients exhibiting
ischemic colitis should raise the suspicion of drug use,
vasculitis, infection, and hypoperfusion status [13]. Thein periodic acid-Schiff stain (original magnification 400). (B)
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detecting kayexalate crystals in necrotic gastrointestinal
tissue. Because kayexalate crystals are easily neglected in
daily practice, pathologists should pay attention to tiny
clues whenever encountering unexplainable gastrointes-
tinal necrosis. Many drugs are known to be associated with
ischemic enterocolitis; however, kayexalate is the only one
that can be directly observed under microscopic examina-
tion [1].
Back to our patient, because he was a young man with
endoscopic findings suggestive of ischemic colitis, this
unusual association deserved thorough survey to discover
any possible underlying etiologies. Tracked down his
medication history, we could find that he had taken oral
kayexalate in sorbitol 3 days before colonoscopic exami-
nation. Additionally, the patient had suffered from chronic
renal failure for 4 years. Other possible explanations for the
colonic necrosis were excluded both clinically and patho-
logically. That is, we could conclude that kayexalate in
sorbitol was the prime cause of the ulcerated lesion
observed under colonoscopy. In fact, the clinical settings
and time sequence were typical for “kayexalate in sorbitol-
associated gastrointestinal tract injury”.
One question existed regarding the initial episode of
bloody stool of our patient, which occurred before the
documented administration of kayexalate and sorbitol. It
was possible that there might be another bleeding point
beyond the examining field of colonoscopy. However, the
assumption could not be proved because further survey
(such as panendoscopy and angiography) was not done. A
similar scenario was reported in 2009 [15]. In that case, the
patient presented with gastritis-related bloody stool in the
beginning. However, drug-induced colonic necrosis was
identified after taking kayexalate for incidentally-found
hyperkalemia. Regardless of the initial cause of bloody
stool, kayexalate in sorbitol contributed to the ulcerated
colonic lesion in our patient, as confirmed by endoscopic
and pathological investigation.
The US Food and Drug Administration has begun issuing
warnings regarding the use of kayexalate powders.
Concomitant administration of kayexalate and sorbitol is
not recommended, because this combination has been
documented to be associated with gastrointestinal injuries.
Alternative vehicles thus have been proposed, including
milk, lactulose, water, and syrup. However, the safety of
delivering kayexalate resin using these solutions requires
further investigation [8]. In patients who had developed
gastrointestinal necrosis associated with kayexalate,
cessation of medication is necessary. In contrast to the
upper gastrointestinal tract injury, which may recoverspontaneously without sequelae, the potentially lethal
ileocolonic necrosis may require surgical intervention.
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